Compound Shows Promise as Next-Generation Prostate Cancer Therapy

Contact: Sarah Avery Phone: 919-660-1306 Email:sarah.avery@duke.eduhttps://www.dukehealth.orgEMBARGOED FOR RELEASE until 11 a.m. (ET) Monday, Aug. 8, 2016DURHAM, N.C. -- In the search for new ways to attack recurrent prostate cancer, researchers at Duke Health report that a novel compound appears to have a unique way of blocking testosterone from fueling the tumors in mice.The potential foundation for a next-generation therapy, called tetraaryl cyclobutane, or CB, is being studied as an option for prostate tumors that have grown resistant to current anti-androgen drugs, notably enzalutamide.“Prostate cancer is the most prevalent form of cancer in men, and the principal driver of tumor growth is the androgen receptor,” saidJohn D. Norris, Ph.D., associate research professor in theDepartment of Pharmacology&Cancer Biology at Duke and senior author of a study published online Aug. 8 in the journal Nature Chemical Biology.“Suppression of androgen receptor function by anti-endocrine therapies is initially effective, but most tumors develop resistance, resulting in a more aggressive cancer,” Norris said. “Our research has been focused on finding a new approach to suppressing androgen receptor activity, because ev en in situations where tumors are resistant to current therapies, the androgen receptor remains a viable target.”Norris and colleagues focused on a group of CB compounds developed in collaboration with scientists at the Universi...
Source: DukeHealth.org: Duke Health Features - Category: Pediatrics Tags: Duke Medicine Source Type: news

Related Links:

Publication date: Available online 19 September 2018Source: Molecular and Cellular EndocrinologyAuthor(s): Trevor M. PenningAbstractAldo-Keto-Reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase (HSD)/prostaglandin (PG) F2α synthase) is the only 17β-HSD that is not a short-chain dehydrogenase/reductase. By acting as a 17-ketosteroid reductase, AKR1C3 produces potent androgens in peripheral tissues which activate the androgen receptor (AR) or act as substrates for aromatase. AKR1C3 is implicated in the production of androgens in castration-resistant prostate cancer (CRPC) and polycystic ovarian syndrome; a...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
CONCLUSIONS: In this practice-based sample of CA-VTE patients, DOACs were associated with similar bleeding risks to warfarin and LMWH. These findings suggest a complex association of bleeding risk with anticoagulant choice in cancer patients. This article is protected by copyright. All rights reserved. PMID: 30240508 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Tags: J Thromb Haemost Source Type: research
ConclusionsProstate cancers that are homogeneously low risk by traditional characteristics demonstrate substantial diversity at the level of genomic expression. Molecular substratification of low-risk prostate cancer will yield a better understanding of its divergent biology and, in the future may help personalize treatment recommendations.Patient summaryWe studied the genomic characteristics of tumors from men diagnosed with low-risk prostate cancer. We found three main subtypes of prostate cancer with divergent tumor biology, similar to what has previously been found in women with breast cancer. In addition, we found tha...
Source: European Urology - Category: Urology & Nephrology Source Type: research
This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: CA Cancer J Clin Source Type: research
[Prevalence and expectations of "alternative and complementary medicine" use during radiotherapy in 2016: A prospective study]. Cancer Radiother. 2018 Sep 06;: Authors: Dupin C, Arsène-Henry A, Charleux T, Haaser T, Trouette R, Vendrely V Abstract PURPOSE: Alternative and complementary medicine is defined as any substance or technique of non-allopathic medicine used to improve health and quality of life. The purpose of this prospective observational study was to evaluate the use of alternative and complementary medicine during radiotherapy. MATERIAL AND METHODS: A questionnaire w...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
Alpha Tau Medical said today it raised $29 million in a private funding round to help support its alpha radiation cancer therapy technology. The round was led by Israeli private equity firm Shavit Capital and joined by global equity crowdfunding platform OurCrowd.com and Medison Pharma venture capital arm Medison Ventures, the Israel-based company said. The round was also joined by Apax Partner founds Ronald Cohen and Alan Patricof, Alpha Tau said. “We are confident that Alpha Tau’s ground-breaking technology can be a game changer in the treatment of cancer. Importantly, under the guidance of an exper...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Funding Roundup Alpha Tau Medical Source Type: news
Authors: Rahouma M, Kamel M, Abouarab A, Eldessouki I, Nasar A, Harrison S, Lee B, Shostak E, Morris J, Stiles B, Altorki NK, Port JL Abstract Purpose: Previous studies have reported that psychological and social distresses associated with a cancer diagnosis have led to an increase in suicides compared to the general population. We sought to explore lung cancer-associated suicide rates in a large national database compared to the general population, and to the three most prevalent non-skin cancers [breast, prostate and colorectal cancer (CRC)]. Methods: The Surveillance, Epidemiology and End Results (SEER) data...
Source: Ecancermedicalscience - Category: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research
Conclusions: Trunk SPECT/CT improves the performance of PBS in BC and PCa assessments and results in improvements in both the detection performance of bone metastases as well as a better characterization of equivocal lesions. PMID: 30167091 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
ConclusionsAltogether, we propose that regulation of energy metabolism contributes to 1,25(OH)2D3’s anti-cancer effects and that combining 1,25(OH)2D3 with drugs targeting metabolic networks in tumor cells may lead to synergistic effects.
Source: Cancer and Metabolism - Category: Cancer & Oncology Source Type: research
CONCLUSION: The study has made an attempt to provide evidence to the idea that GBX2 gene silencing has an inhibition effect on the proliferation, invasion and angiogenesis of the breast cancer cells by inhibiting the activation of the Wnt/β-catenin signaling pathway. PMID: 30223390 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers : Section A of Disease Markers - Category: Cancer & Oncology Authors: Tags: Cancer Biomark Source Type: research
More News: Biology | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Drugs & Pharmacology | Endocrine Therapy | Health | Legislation | National Institutes of Health (NIH) | Pediatrics | Politics | Prostate Cancer | Research | Study